Back

Acoramidis reduces days lost to death and/or cardiovascular-related hospitalization, preserving time alive outside the hospital in participants with ATTR-CM: results from ATTRibute-CM

30 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Real-world cardiovascular care: health economics, resource use, and long-term outcomes Health Economics ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Richard Wright

(United States of America)

5 More presentations in this session

Presentation thumbnail
Ten-year drug consumption for rare cardiovascular diseases in 66 countries and regions: a multinational drug utilization analysis
Doctor O. Chou (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
Economic evaluation of a large-focal lattice tip catheter versus conventional radiofrequency catheter, for persistent atrial fibrillation ablation, from a German healthcare payer perspective.
Professor R. Wakili (Frankfurt, DE)
Abstract Slides Video
Presentation thumbnail
The association between body roundness index (BRI) in middle-aged adults and long-term all-cause mortality risk
Mrs E. Friedman Shamay (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Healthcare resource utilization (HCRU) and disease burden of hypertrophic cardiomyopathy: a nationwide population-based study from Sweden
Associate Professor O. Braun (Lund, SE)
Abstract Slides Video
Presentation thumbnail
Impact of health insurance on long-term mortality after percutaneous coronary intervention in acute coronary syndrome patients: a nationwide propensity-weighted analysis
Mr S. Chumsantivut (Bangkok, TH)
Abstract Slides Video

Access the full session

Session thumbnail
Real-world cardiovascular care: health economics, resource use, and long-term outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
18 May 2025
thumbnail
Congress Session
Time matters in transthyretin amyloid cardiomyopathy (ATTR-CM): emerging artificial intelligence approaches to screening and clinical considerations for treatment timing
28 August 2026
thumbnail
Congress Presentation
Tafamidis treatment significantly reduces the risk of recurrent cardiovascular-related hospitalisation in patients with early stage transthyretin amyloid cardiomyopathy
31 August 2025
thumbnail
Congress Presentation
Health-related quality of life in patients with symptomatic transthyretin amyloid cardiomyopathy treated with acoramidis: an EQ-5D analysis from the ATTRibute-CM study
13 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources